Objective: Describe the clinical course and diagnostic and genetic findings in a cat with X-linked myotubular myopathy.

Case Summary: A 7-month-old male Maine coon was evaluated for progressively worsening gait abnormalities and generalized weakness. Neurolocalization was to the neuromuscular system. Genetic testing for spinal muscular atrophy (LIX1) was negative. Given the progressive nature and suspected poor long-term prognosis, the owners elected euthanasia. Histopathology of skeletal muscle obtained post-mortem disclosed numerous rounded atrophic or hypotrophic fibers with internal nuclei or central basophilic staining. Using oxidative reactions mediated by cytochrome C oxidase and succinic dehydrogenase, scattered myofibers were observed to have central dark staining structures and a "ring-like" appearance. Given the cat's age and clinical history, a congenital myopathy was considered most likely, with the central nuclei and "ring-like" changes consistent with either centronuclear or myotubular myopathy. Whole genome sequencing identified an underlying missense variant in myotubularin 1 (MTM1), a known candidate gene for X-linked myotubular myopathy.

New Or Unique Information Provided: This case is the first report of X-linked myotubular myopathy in a cat with an MTM1 missense mutation. Maine coon cat breeders may consider screening for this variant to prevent production of affected cats and to eradicate the variant from the breeding population.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511081PMC
http://dx.doi.org/10.1111/jvim.16509DOI Listing

Publication Analysis

Top Keywords

x-linked myotubular
16
myotubular myopathy
12
maine coon
12
coon cat
8
x-linked
4
myopathy
4
myopathy associated
4
associated mtm1
4
variant
4
mtm1 variant
4

Similar Publications

Potential compensatory mechanisms preserving cardiac function in myotubular myopathy.

Cell Mol Life Sci

December 2024

Institute of Genetics and Molecular and Cellular Biology (IGBMC), INSERM U1258, CNRS UMR7104, University of Strasbourg, 1 rue Laurent Fries, Illkirch, 67404, France.

Article Synopsis
  • X-Linked myotubular myopathy (XLMTM) leads to significant muscle weakness and shorter life expectancy, with unclear impacts from non-muscular issues like liver problems.
  • Research using an Mtm1 mouse model involved RNA-sequencing to understand the disease's effects on skeletal muscles and to check heart and liver functions.
  • Findings showed skeletal muscle issues related to muscle development and inflammation, while the heart maintained function through compensatory mechanisms, suggesting potential areas for treatment focused on muscle defects in XLMTM.
View Article and Find Full Text PDF

X-linked myotubular myopathy (XLMTM) is a rare, life-threatening congenital myopathy. Most (80%) children with XLMTM have profound muscle weakness and hypotonia at birth resulting in severe respiratory insufficiency, the inability to sit up, stand or walk, and early mortality. At birth, 85-90% of children with XLMTM require mechanical ventilation, with more than half requiring invasive ventilator support.

View Article and Find Full Text PDF

Drug-induced liver injury related to gene therapy: A new challenge to be managed.

Liver Int

December 2024

Department of Hepato-Gastroenterology, Cliniques Universitaires Saint-Luc et Institut de Recherche Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.

Gene therapy is being successfully developed for the treatment of several genetic disorders. Various methods of gene transfer have been developed to enable the production of the deficient enzyme or protein. One of the most important is adeno-associated virus vectors, which have been shown to be viable for use in in vivo gene therapy.

View Article and Find Full Text PDF

What is in the Myopathy Literature?

J Clin Neuromuscul Dis

September 2024

Departments of Neurology and Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA.

Article Synopsis
  • The update covers advancements in inflammatory myopathies, highlighting research on inclusion body myositis, the role of anti-cN1A antibodies, and the results of a negative trial for arimoclomol.
  • It discusses potential treatments for dermatomyositis using Janus kinase inhibitors and therapeutic strategies for complications from immune checkpoint inhibitors.
  • The report also explores therapies for inherited myopathies, including promising gene replacement results for Duchenne muscular dystrophy and emerging understanding of other muscular dystrophies and myopathies related to specific genetic mutations.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!